Immunex' Leukine and Amgen's Neupogen recommended for PBSC-mobilization in transplantation.
IMMUNEX LEUKINE AND AMGEN NEUPOGEN USE IN PBSC TRANSPLANTS reduce time to engraftment and neutrophil and platelet recovery, FDA's Biological Response Modifiers Advisory Committee agreed at its Nov. 13 review of the companies' supplemental NDAs. The data on mobilization of peripheral blood stem cells for transplantation by the granulocyte-macrophage and granulocyte colony stimulating factors were collected by the companies at the request of the advisory committee, which noted that the indication already has become standard practice in the clinical setting.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth